

$Arazlo^{^{TM}}$ (tazarotene) – New drug approval

- On December 19, 2019, <u>Bausch Health announced</u> the FDA approval of <u>Arazlo (tazarotene)</u> lotion, for the topical treatment of acne vulgaris in patients 9 years of age and older.
- Arazlo is the first tazarotene acne treatment available in a lotion formation. Tazarotene is currently available generically as a topical cream and brand topical foam (Fabior®), topical gel (Tazorac®), and another brand cream (Avage®). Tazarotene is also available as a lotion in combination with halobetasol (Duobrii™).
 - The generic topical cream and gel are approved for plaque psoriasis and acne vulgaris. The topical foam is approved for acne vulgaris.
 - Avage is approved as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper- and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs.
 - Duobrii is approved for the treatment of plaque psoriasis.
- The efficacy of Arazlo was established in two randomized, double-blind studies in 1,614 patients with facial acne vulgaris. Patients received Arazlo or vehicle. The efficacy endpoints of success on the Evaluator's Global Severity Score (EGSS), absolute change in non-inflammatory lesion count, and absolute change in inflammatory lesion count were assessed at week 12. Success on the EGSS was defined as at least a 2-grade improvement from baseline and an EGSS score of clear (0) or almost clear (1).
 - In study 1, success on the EGSS was achieved in 25.5% and 13% of patients receiving Arazlo and vehicle, respectively (difference 12.5, 95% CI: 7.1, 17.9). The mean absolute reduction in non-inflammatory facial lesions was 21.0 and 16.4, respectively (difference 4.5, 95% CI: 2.6, 6.4) and the mean absolute reduction in inflammatory facial lesions was 15.6 and 12.4 (difference 3.3, 95% CI: 1.9, 4.7).
 - In study 2, success on the EGSS was achieved in 29.6% and 17.3% of patients receiving Arazlo and vehicle, respectively (difference 12.3, 95% CI: 6.5, 18.1). The mean absolute reduction in non-inflammatory facial lesions was 24.6 and 16.6, respectively (difference 8.1, 95% CI: 5.9, 10.2) and the mean absolute reduction in inflammatory facial lesions was 16.7 and 13.4 (difference 3.2, 95% CI: 1.9, 4.5).
- Arazlo is contraindicated in pregnancy.
- Warnings and precautions for Arazlo include embryofetal toxicity, skin irritation, and photosensitivity and risk for sunburn.
- The most common adverse reactions (≥ 1% and greater than the vehicle group) with Arazlo use were application site reactions: pain, dryness, exfoliation, erythema and pruritus.
- The recommended administration of Arazlo is a thin layer to the affected areas once daily.
- Bausch Health plans to launch Arazlo in the first half of 2020. Arazlo will be available as a 0.045% lotion



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.